3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Carcinoma, Renal Cell
35
Carcinoma, Hepatocellular
17
Neoplasm Metastasis
15
Prostatic Neoplasms
13
Neoplasms
9
Neuroendocrine Tumors
7
Carcinoma, Non-Small-Cell Lung
7
Breast Neoplasms
6
Brain Neoplasms
6
Sarcoma, Ewing
5
Sarcoma
5
Osteosarcoma
5
Kidney Neoplasms
5
Colorectal Neoplasms
5
Carcinoma, Transitional Cell
5
Recurrence
4
Pancreatic Neoplasms
4
Multiple Myeloma
4
Clear-cell metastatic renal cell carcinoma
4
Urinary Bladder Neoplasms
3
Lung Neoplasms
3
Carcinoid Tumor
3
Adenocarcinoma
3
Uterine Cervical Neoplasms
2
Thyroid Neoplasms
2
Thyroid Diseases
2
Pheochromocytoma
2
Paraganglioma
2
Neurofibroma, Plexiform
2
Melanoma
2
Interventions
lutetium Lu 177 dotatate
5
copper dotatate CU-64
3
Magnetic Resonance Spectroscopy
3
lanreotide
2
gallium Ga 68 dotatate
2
Nivolumab
2
Lutetium-177
2
Lutetium
2
Ga(III)-DOTATOC
2
Carboplatin
2
177Lu-octreotide, DOTA(0)-Tyr(3)-
2
zimberelimab
1
regorafenib
1
pembrolizumab
1
pasireotide
1
irinotecan sucrosofate
1
folfirinox
1
cabozantinib
1
abemaciclib
1
X-Rays
1
Temozolomide
1
Somatostatin
1
Resveratrol
1
Radiosurgery
1
Octreotide
1
Ipilimumab
1
Granulocyte Colony-Stimulating Factor
1
Fluorodeoxyglucose F18
1
Filgrastim
1
Etoposide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Gastro-enteropancreatic neuroendocrine tumor
×
cabozantinib
×
Clear all
NCT04893785
2024-06-18
CABOTEM
National Cancer Institute, Naples
Phase 2
Recruiting
35 enrolled